

### EXHIBIT 3 Timeline

Late 1970s	Zantac developed by Glaxo
1977	Tagamet introduced to U.S. market by SmithKline
1981	Zantac drug available for sale
1989	SmithKline Beckman and the Beecham Group merge to form SmithKline Beecham
1992	IRS begins audit of Glaxo's tax returns for 1989 and 1990
1993	IRS and SmithKline Beecham reach agreement over outbound transfer price for Tagamet
1994	IRS and Glaxo attempt to resolve dispute through the APA process
1995	Glaxo and Wellcome merge to form GlaxoWellcome
By 1999	GlaxoWellcome and U.K. taxing authorities agree upon transfer price
Dec. 1999	GlaxoWellcome requests relief under Convention for the Avoidance of Double Taxation
Dec. 2000	GlaxoWellcome merges with SmithKline Beecham to form GlaxoSmithKline
May 2001	Joint motion to allow depositions filed and approved by Tax Court
2004	GSK sues IRS for discriminatory practices in the APA process
Sep. 11, 2006	IRS and GSK announce a settlement of \$3.4 billion covering tax years 1989 to 2005